EcoDrugPlus

Glutamate Receptor 1-Like

Ensembl ID : ENSCGOG00000016429
Gene Symbol: LOC115014340
3 Cross references
252 Possible Orthologues:

Glutamate Receptor 1-Like

Ensembl ID : ENSCGOG00000010886
Gene Symbol: LOC115018541
2 Cross references
250 Possible Orthologues:

Glutamate Receptor 2-Like

Ensembl ID : ENSCGOG00000016318
Gene Symbol: LOC115014292
3 Cross references
244 Possible Orthologues:

Glutamate Receptor 3-Like

Ensembl ID : ENSCGOG00000013291
Gene Symbol: LOC115019253
3 Cross references
254 Possible Orthologues:

Glutamate Receptor 4-Like

Ensembl ID : ENSCGOG00000006893
Gene Symbol: LOC115019197
3 Cross references
252 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2a-Like

Ensembl ID : ENSCGOG00000007729
Gene Symbol: LOC115008985
2 Cross references
225 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2b-Like

Ensembl ID : ENSCGOG00000019435
Gene Symbol: LOC115006909
3 Cross references
256 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSCGOG00000010853
Gene Symbol: LOC115015571
2 Cross references
215 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSCGOG00000017415
Gene Symbol: LOC115020942
2 Cross references
213 Possible Orthologues:

Glutaminase Kidney Isoform, Mitochondrial-Like

Ensembl ID : ENSCGOG00000021597
Gene Symbol: LOC115025986
2 Cross references
225 Possible Orthologues:

Glutaminase Kidney Isoform, Mitochondrial-Like

Ensembl ID : ENSCGOG00000006267
Gene Symbol: LOC115017326
3 Cross references
236 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSCGOG00000020623
Gene Symbol: GSK3B
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).